Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1642 1643 1644 1646 1647 1671
This examiner grants 62% of resolved cases
Julie Zhen Qin Wu works in Art Unit 1600 of Tech Center 1600. She has 363 resolved cases and an allowance rate of 62.0%. The median days to allowance is 1198, reflecting the thorough nature of biological and chemical examinations. These figures suggest that while the process is detailed, there is a solid probability of eventually securing a patent. Practitioners should be prepared for a timeline that exceeds three years on average.
The interview lift is 50.7%, which is exceptionally high. This suggests that interviews are a critical component of a successful prosecution strategy with this examiner. Practitioners should prioritize scheduling interviews to maximize their chances of overcoming rejections, as the lift nearly doubles the likelihood of success. The 363 resolved cases show a significant history of examination within the unit. With a 62.0% allowance rate and a 50.7% lift, the data strongly supports active engagement through oral advocacy to navigate the 1198-day prosecution period.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17635054 | CAR-T CELLS SPECIFIC FOR MODIFIED PROTEINS IN EXTRACELLULAR SPACES | Non-Final OA | The Regents of the University of California |
| 17998605 | SARS-COV2 NEUTRALIZING SINGLE DOMAIN ANTIBODY CONSTRUCTS | Final Rejection | REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18061221 | METHODS OF TREATING ANKYLOSING SPONDYLITIS USING IL-17 ANTAGONISTS | Non-Final OA | Novartis AG |
| 17605061 | MEANS AND METHODS FOR TREATING BURKITT LYMPHOMA OR LEUKEMIA | Final Rejection | AMGEN RESEARCH (MUNICH) GMBH |
| 17400689 | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY | Final Rejection | MEMORIAL SLOAN-KETTERING CANCER CENTER |
| 17312317 | Screening Assays, Modulators and Modulation of Intracellular Signalling Mediated by Immunoglobulin Superfamily Cell Adhesion Molecules | Final Rejection | The University of Western Australia |
| 17621993 | CD3 ANTIGEN BINDING FRAGMENTS AND COMPOSITIONS COMPRISING SAME | Final Rejection | AMUNIX PHARMACEUTICALS, INC. |
| 17915837 | EPITOPE REGION-BRIDGING BIPARATOPIC ANTIBODY AND METHOD FOR PRODUCING SAME | Non-Final OA | NATIONAL INSTITUTES OF BIOMEDICAL INOVATION, HEALTH AND NUTRITON |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy